anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
* Alcohol consumption represents the second main modifiable risk factor for cancer and the second preventable mortality cause in France, after tobacco use. It is mainly during adolescence, which corresponds to a period of integration with peers and a period of detachment from parents, that alcohol use starts. In France, alcohol remains the substance that adolescents most experiment with. A 2014 report shows that nearly half (49.4%) of first-year secondary school pupils have already tried an alcoholic drink and about one in seven secondary school pupils' reports having been drunk. The impact of cannabis consumption is wide as it can affect the social environment, the brain and the psychology of the consumers. Adolescence is a period during which the brain undergoes profound remodelling in areas that are high in cannabinoid receptors and that mediate cognitive control and emotion regulation. Therefore, childhood and adolescence are important stages of life on which preventive efforts may be focused, also because events occurring in the earliest stages of human development (before birth and during childhood) are known to be related to further risk for cancer, other chronic diseases and adult conditions.
* Among addiction prevention programmes, those that focus on life skills have been mentioned in the literature as being effective. In this context, the French organization "Association Ressources et Initiatives Addictions" (ARIA) has developed Expériences Animées programme (animated experiences) based on the above features, with the aim to help adolescents to change their representations and strengthen their life skills. This is a grassroots innovation. It has to be evaluated.
* The Expériences Animées programme involves supervised short movies and talks with secondary and high school pupils about the use of psychoactive substances. The movies are made specifically for the programme. The sessions are facilitated by two professionals including at least a clinical psychologist. In a given secondary/high school, one session per term is delivered for each class (40 classes). Three to five films are shown at each session. Each film aims to work on 2 to 3 life skills allowing to build protective behaviors against addictions. This programme is implemented since 2015.
* The investigators will collect quantitative and qualitative data to appraise the outcomes (O), mechanisms (M) and contextual elements (C), including the interventional elements) in order to verify the initial theories (hypothesis of causal pathways) by i) Questionnaires to collect outcomes in terms of consumption and health care, and some mechanisms: 2/ Non-directive interviews to collect mechanisms and contextual factors 3/ Observations to collect contextual elements during the sessions. The investigators will design the survey instruments in line with the initial middle-range theories identified.
This is an open label, single arm, phase II clinical trial designed to evaluate the safety and efficacy of the treatment regimen. Efficacy will be measured by long-term engraftment of the transplanted cells.The primary endpoint of neutrophil engraftment is defined as an absolute neutrophil count (ANC) \>5 x 108/L (first of three consecutive laboratory measurements on different days) with at least 10% donor cells by day 100. We will evaluate the proportion of success (P) and its 95% confidence interval (CI) for the entire group. The null hypothesis of 90% engraftment will be rejected if 4 or more patients fail to engraft out of 15 evaluable patients. The secondary endpoints of regimen related mortality, acute and chronic graft-versus-host disease (GVHD) and secondary malignancies will be estimated by cumulative incidence treating non-event deaths as a competing risk. Survival will be estimated by Kaplan-Meier methods. Immune reconstitution will be summarized with descriptive statistics.

SAA and DC arms will be analyzed separately.
PURPOSE:A cosmetic having improved spread, improved adhesivity, smoothness, covering power, luster and improved moldability, containing nonswelling or limitedly swelling type synthetic mica shown by a specific structural formula. CONSTITUTION:A cosmetic containing 0.1-99wt% synthetic mica shown by the formula I (commas in parentheses show and/or). The synthetic mica does not swell in water at all or swells but neither is processed into fine particles nor dispersed and, for example, is obtained by blending 40pts.wt. silicic anhydride with 30pts.wt. magnesium oxide, 13pts.wt. aluminum oxide and 17pts.wt. potassium silicofluoride, melting the blend at 1,400-1,500 deg.C and crystallizing at 1,300-1,400 deg.C in the case of fluorine Phlogopite shown by the formula II. Further low deteriorating action on perfume and oil may be cited as characteristics of the cosmetic.
PURPOSE: A CD300A synthetic peptide and a composition for modulate immune response containing the same are provided to seclude signal transmission path mediated by TLR in order to prevent or treat diseases by immune response modulation dysfunction. CONSTITUTION: A CD300A synthetic peptide has the amino acid sequence described in the sequence number 1(SEQ ID NO:1) or 2. The CD300A synthetic peptide includes the ITIM(immunoreceptor tyrosine-based inhibitory motif) sequence originated from the CD300A. The CD300A synthetic peptide obstructs the signal transmission path mediated by TLR(Toll-like receptor). The CD300A synthetic peptide obstructs the signal transmission mediated by TLR4 or TLR9MyD88 by controlling the signal transmission mediated by MyD88. The expression of MMP and IL-8 is controlled by secluding the TLR signal transmission path. The composition for immune response modulation includes CD300A specific monoclonal antibody which can trigger the CD300A activation or CD300A synthetic peptide as an active ingredient. The composition for treating and preventing immunological disorder contains the composition for modulating immune response. The immunological disorder is autoimmune disease and inflammation disease.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the world. HCC is often diagnosed late because patients with early-stage cancer have no apparent symptoms. Therefore, it is desirable to find a reliable method for an early diagnosis based on the detection of metabolites - biomarkers, that can be detected in the early stages of the disease. Untargeted metabolomics is often used as a tool to find a suitable biomarker for several diseases. In this work, untargeted metabolomics was performed on blood plasma samples of HCC patients and compared with healthy individuals and patients with liver cirrhosis. A combination of liquid chromatography and high-resolution mass spectrometry was used as an analytical method. More than a thousand peaks were detected in the blood plasma samples, from which mainly amino acids, carboxylic acids, lipids, and their derivatives were evaluated as potential biomarkers. The data obtained were statistically processed using the analysis of variance, correlation analysis, and principal component analysis.
The invention concerns the human mitochondrial cadherin 10.12 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique.  The methods for treating many diseases e.g. embryo developmental dysmorphia, a variety of tumor etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes the human mitochondrial cadherin 10.12.
1,221,232. Shampoos. COLGATE-PALMOLIVE CO. 8 May, 1968 [12 May, 1967], No. 21723/68. Heading C5D. A shampoo composition comprises in an aqueous medium a water-soluble non-soap organic synthetic detergent having a long chain containing at least 8 carbon atoms in its molecular structure and a liquid saturated branched-chain higher (C 12 -C 24 ) fatty acid and/or its salt, the ratio of the synthetic detergent to the branched-chain fatty acid material being from 80 : 1 to 1 : 1 by weight and being such as to render the composition effective simultaneously to clean and condition human hair during use as a foaming shampoo. Examples of suitable detergents are organic sulphates, sulphonates, fatty acid amides of long-chain amino acid compounds, ampholytic detergents, and nonionics such as ethylene oxide condensates and fatty acid alkanolamides. The branched-chain higher fatty acid may be, for example, isostearic acid or isomers of lauric, myristic or palmitic acids with mainly methyl or ethyl branching at about the middle of the chain. The fatty acid may be partially neutralized to give a water-soluble soap and fatty acid mixture. A suitable composition contains 10-40% of the detergent and 0À1 to 10%, preferably 0À5-5% of isostearic acid having a titre of 10‹ C. maximum, the pH of the composition being 5 to 8À5. 0À5 to 10% of an opacifying agent, such as lanolin or ethylene glycol mono- or di-stearate, may be included in the composition. It is preferred to add an alkylolamide of a fatty acid, such as diethanolamides, monoethanolamides and isopropanolamides of fatty acids having 8-18 carbon atoms, in minor amounts (1 to 10%) to the shampoo. Other optional additives are perfume, colour, borax, alkali metal phosphates, citric acid, lanolin or ethoxylated lanolin, E.D.T.A. salts, fatty alcohols, other fatty acids and their esters, glycerine, ethanol, propylene glycol, sodium benzoate, carboxymethyl cellulose, bactericides, and antiseptics.
Zoonotic transmission of bovine spongiform encephalopathy or mad cow disease, by presumed consumption of infected beef, has increased awareness of the public health risk associated with prion diseases. Chronic wasting disease (CWD) affects moose, elk, and deer, all of which are frequently consumed by humans. Clear evidence of CWD transmission to humans has not been demonstrated, yet, establishing whether CWD prions are present in muscle tissue preferentially consumed by humans is of increasing interest. Conventional assays including immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) lack the sensitivity to detect low concentrations of prions presumed to be present outside neural or lymphatic tissues. Here we combined two prion amplification assays, the product of protein misfolding cyclic amplification (PMCA) applied directly into real-time quaking induced conversion (RT-QuIC) [denoted now as PQ] to demonstrate the presence of prion seeding activity (i.e. prions) in ~55% of hamstring muscles harvested from CWD-positive white-tailed deer. This compares to prion detection in only 10% of the same samples employing standard RT-QuIC. To determine the extent of CWD dissemination within muscle tissues commonly consumed we tested 7 additional muscles from a subset of deer by PQ. Tongue demonstrated the highest level of prions with ~92% positive. All negative controls remained negative in all PMCA and RT-QuIC assays. We conclude that the combination of PMCA with RT-QuIC readout permits detection of low prion concentrations present in muscle tissue of CWD-infected deer. These findings further demonstrate the utility of amplification assays as tools to detect very low levels of prion burden and supports their use to fill knowledge gaps in our understanding of CWD pathogenesis and zoonotic potential.
<P>PROBLEM TO BE SOLVED: To provide a method of identifying an agent that modulates an immune response.  <P>SOLUTION: Using the method, interaction between B7 polypeptide and PD-1 ligand is blocked. The method includes abutting of an immune cell having PD-1 ligand or that having B7 polypeptide on the agent for blocking the interaction between the PD-1 ligand and the B7 polypeptide. The interaction between the B7 polypeptide and the PD-1 ligand polypeptide prevents bonding of the PD-1 ligand to the PD-1, thus blocking transmission of a blocking immune signal. The agent for blocking the interaction between the PD-1 and the PD-1 ligand can block transmission of the blocking signal. The agent for blocking the bonding of the PD-1 ligand to the B7 polypeptide allows the PD-1 ligand to be bonded to the PD-1, provides the immune cell with the blocking signal, and reinforces blocking of signal transmission.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE: To carry out powerful bleaching without deteriorating keratin fiber by proving an orifice as an exit of laser beam in the surface of a socket for hair cluster in a treating apparatus and irradiating the hair with laser beam with a specific energy density emitted in the form of pulse. CONSTITUTION: A conduit 3 for laser beam appears externally on the bottom portion of groove 2 after being reflected sharply by a mirror 4, and forms an exit window in the surface of the wall of groove 2. A common member 5 can move around an axis 6 to maintain the state of engaging tightly with a socket by a tensile spring, and the engagement is released by the action of a lever 7 at the end portion. For bleaching hair, the engagement of the member 5 is released, then engaged again in the groove 2 after the cluster of hair being placed. A laser emitter is actuated and the apparatus is moved to the cluster of hair thus performing bleaching. Here, the operation is carried out by employing a laser beam with a sufficient output that the energy density per pulse is 0.1 to 1.2 J/cm.
The worldwide HIV/AIDS epidemic may only be controlled through the development of a safe and effective vaccine that will prevent HIV infection. DNA-based vaccines alone promote a weak immune response but when used as priming immunogens, followed by a recombinant viral vaccine that is a very attenuated vaccinia (smallpox) vaccine presenting the same immunogens as a booster, immunization with such a combination regimen seems to induce much stronger responses. EP-1233 is a DNA-HIV-recombinant vaccine designed to interact with CD4 (helper-inducer) and CD8 (cytotoxic) T lymphocytes (T cells) to prime CD4 and CD8 cells to respond to HIV components. MVA-mBN32 is a HIV-recombinant viral (MVA) vaccine that through other ways of interacting with CD4 and CD8 cells to immunize (boost) with similar HIV immunogens, may result in a stronger immune response.

The purpose of this study is to determine the safety of and immune response to two experimental vaccines for the prevention of HIV infection, individually and in combination, in healthy adults who have not been previously vaccinated against smallpox. Participants will be randomly assigned to one of three groups. All participants will receive injections at Days 0, 28, 84, and 168 of the study. Participants assigned to Group 1 will receive, on Day 0, one injection in each arm of EP-1233 or placebo and the same study product (EP-1233 or the DNA placebo) on Day 28. Thereafter, each Group 1 participant will receive one injection of MVA-mBN32 or placebo on Days 84 and 168. Groups 2 and 3 will not begin enrollment until safety and immunogenicity data from Group 1 have been evaluated. Participants assigned to Group 2 will receive only the DNA vaccine EP-1233 (or placebo) in each arm on all injection days. Participants in Group 3 will not begin enrollment until safety and immunogenicity data from Group 1 have been evaluated. Participants assigned to Group 3 will receive a consistent regimen of MVA-mBN32 (or placebo) on all injection days. Participants will be required to keep a symptom log for 3 days after each injection and attend clinical visits on Day 0, 14, 28, 42, 84, 98, 168, 182, 273, and 364 of the study. At each of the 10 visits, a physical exam, cardiac assessment, and HIV risk reduction and prevention counseling will occur. Blood collection will occur on Days 0, 14, 42, 98, 182, 273, and 364. Urine collection will occur on Days 14, 42, 98, and 182.
BACKGROUND: This study aims to explore the priorities and counselling needs of patients with muscle-invasive bladder cancer faced with a decision between radical cystectomy and trimodality therapy.
METHODS: We performed a qualitative study according to the phenomenological approach. Sixteen muscle-invasive bladder cancer survivors who underwent radical cystectomy or trimodality therapy completed a semi-structured interview between May 2022 and February 2023. Patients were recruited via Ghent University Hospital and a patient organisation. Data were analysed with inductive thematic analysis by a multi-disciplinary team using an iterative approach and investigators' triangulation.
RESULTS: Four main priorities determining the treatment decision were identified. (1) curing the disease; (2) health-related quality of life (physical, mental and social); (3) confidence in the treatment, which was mainly based on trust in the clinician; and (4) personal attributes. Trust in the clinician can be achieved by fulfilling the patient's information needs (accurate, complete, clear, impartial, personalised, realistic, and transparent information), ensuring accessibility of the clinician, and creating a clear and personalised treatment plan, involving patients to the extend they desire. Many patients considered a patient decision aid as a valuable asset in this process.
CONCLUSION: Priorities vary between patients with muscle-invasive bladder cancer. Identifying individual priorities and offering personalised information about them is crucial for ensuring trust in the clinician and confidence in the treatment. Use of a patient decision aid can be beneficial in this process.
Third and fourth branchial arch anomalies belong to congenital lesions which are extremely rare accounting for <1-4% of branchial arch anomalies. In our case, a 4-year-old boy was admitted to our hospital with a painful mass on the left side of his neck. The imaging and clinical findings are oriented to the diagnosis of suppurative thyroiditis with underlying third/fourth branchial arch anomaly. The diagnosis was confirmed with laryngoscopy and the child was treated with endoscopic cauterization. The presence of specific clinical and imaging findings is not definitive, so the diagnosis relies on having a strong suspicion and knowledge of typical locations. So, our purpose is to present the spectrum of relative imaging findings from at least three imaging modalities in order to increase the level of clinical and radiological suspicion of that rare condition and help with accurate diagnosis and planning of the treatment.
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to the pharmaceutical industry, specifically to a liquid antacid composition. Liquid antacid composition containing: antacid; citrus extract; and optionally one or more other pharmaceutically acceptable excipients; where the citrus extract is present in amount of 0.025 % to 1.90 % and where the citrus extract is a water-soluble extract of citrus fruit selected from citrus aurantium amara (CAS 72968-50-4), citrus reticulata (CAS No. 84929-38-4) and citrus sinensis (CAS 8028-48-6). Use of a liquid antacid composition for neutralizing an excess of gastric acid in an individual or a lower animal, involving oral administration of an effective amount of a liquid antacid composition to said human or lower animal. Use of a liquid antacid composition for treating a gastrointestinal disorder in a human or a lower animal, comprising administering to said human or lower animal an effective amount of a liquid antacid composition. Composition described above provides excellent resistance to growth of microorganisms without detriment to acid neutralizing activity of the antacid; the composition has an improved taste.EFFECT: when using said composition there is no increase on 14and 28days relative to the initial counted number for bacteria, yeast and mould.13 cl, 1 tbl, 1 ex
The invention relates to a traditional Chinese medicine composition for treating recurrent oral ulcer, which comprises the following raw material medicines: radix astragali, Gypsum Fibrosum, rhizoma anemarrhenae, radix rehmanniae, rhizoma Smilacis Glabrae, homo, rhizoma picrorhizae, folium Bambusae, rhizoma Bistortae, radix Paeoniae Rubra, cortex moutan, and BIYUSAN. The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating recurrent oral ulcer. Its advantages are: 1. the selected raw material medicines of the invention have accurate and complete dialectics and good curative effect. 2. The traditional Chinese medicine composition and the proportion thereof have the advantage of obvious effect after experimental screening. 3. The raw material medicines of the invention have wide sources, the preparation method is simple and the cost is low. The effect is obvious.
Compositions and methods for the treatment of osteoporosis and/or inflammatory joint disease are provided herein. The compositions contain a folate, such as a reduced folate, and folic acid. The folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The folate and folic acid can be given in the same dosage unit or separate dosage units, and more than one dosage unit can be given per dose. The compositions may also contain one or more vitamins and minerals selected from vitamin B12, vitamin B6, vitamin D3, calcium, magnesium, and polyunsaturated fatty acids (PUFAs). These ingredients are optional, but preferable (especially the vitamins and minerals). The compositions may further contain one or more additional ingredients such as vitamins, minerals, and laxatives. The compositions are useful in the treatment of all forms of osteoporosis, including primary osteoporosis and secondary osteoporosis, and/or inflammatory joint diseases, especially in patients having a folic acid metabolism deficiency. The compositions are particularly useful in the treatment of inflammatory joint diseases, with complications that include bone loss, fracture, and osteoporosis. In addition, the compositions are beneficial for the prevention of osteoporosis in subjects who do not yet have the disease, but who are at risk for getting osteoporosis, such as post-menopausal women, subjects with osteopenia (mid thinning of the bone mass), subjects with an inflammatory joint disease, or people who are over the age of 70.
PURPOSE: A vaccine composition containing Salmonella mutant strain in which Ion and cpxR genes are deleted for preventing fowl typhoid is provided to easily produce and store a live vaccine. CONSTITUTION: A vaccine composition for preventing fowl typhoid contains Salmonella mutant strain in which Ion and cpxR genes are deleted. The Salmonella is Salmonella typhimurium, S. typhi, S. paratyphi, S. sendai, Salmonella Gallinarum, or S. enteritidis. The vaccine composition is administered through oral, transdermal, subcutenous, or nasal cavity administration. The vaccine composition prevents fowl typhoid by administering to birds such as chicken, duck, turkey, waterfowl, and pigeon. A feed additive contains the vaccine composition.
Sleeping in elevated body position (\>30 degrees from supine position) for 4 weeks is a requirement for the intervention group. Patients can define their own most comfortable position during the night.